Cannabis Research in 2025 Highlights Innovations and Challenges
Cannabis research in 2025 reveals key industry trends, including cannabinoid hyperemesis syndrome insights and the effects of delta-8 THC
Key Points
- 1Veterans Action Council discusses cannabinoid hyperemesis syndrome
- 2Mandatory warning signs for cannabis use during pregnancy studied
- 3Delta-8 THC effects compared to delta-9 THC in new research
- 4Inaccurate CBD product labeling remains an industry issue
- 5Hemp-derived beverages linked to improved well-being and reduced alcohol use
The year 2025 has ushered in significant developments in cannabis research, highlighting both innovations and ongoing challenges within the industry. On January 17, the Veterans Action Council (VAC) hosted its 84th Roundtable, focusing on cannabinoid hyperemesis syndrome (CHS) with insights from neurologist Dr. Ethan Russo. The VAC, established in 2020, is dedicated to policy reform and enhancing healthcare access, particularly through natural medicines like cannabis. Dr. Russo, who co-authored a study on CHS, addressed numerous questions from VAC members, emphasizing the syndrome's genetic susceptibility
In parallel, recent studies have explored the effectiveness of mandatory warning signs (MWS) about cannabis use during pregnancy in five U.S. states. Published in the Journal of Studies on Alcohol and Drugs, the research highlights a gap in public health policy, particularly the lack of input from the public regarding these warning signs. The study, funded by the California Department of Cannabis Control, underscores the need for more comprehensive public health strategies that incorporate consumer perspectives
Further research published in Drug and Alcohol Dependence has shed light on the psychoactive effects of delta-8 THC compared to the more commonly known delta-9 THC. Conducted by Johns Hopkins University, this groundbreaking study involved 19 participants consuming brownies infused with synthetic cannabinoids. The findings revealed that while delta-8 THC produces milder psychoactive effects than delta-9 THC, the implications for consumer safety and regulatory oversight remain significant
The accuracy of cannabis product labeling continues to be a concern, as evidenced by a study from the University of Kentucky. Researchers found discrepancies in the labeling of CBD products, particularly in CBG gummies purchased online. This study utilized advanced analytical techniques to assess product content, highlighting the ongoing need for stringent quality control in the cannabis industry. Meanwhile, MoreBetter Ltd's research suggests that low-dose hemp-derived beverages may offer public health benefits, reducing alcohol consumption and improving well-being. The company urges lawmakers to consider these findings when voting on the FY 2026 Agriculture–FDA Appropriations Bill